Serum Androgens as Predictive Biomarkers: Results From a Randomized Clinical Trial Comparing Enzalutamide and Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer
Pre-treatment serum testosterone levels may be a clinically useful biomarker for predicting mCRPC treatment responses and guiding treatment selection.
Authors
- Peter Busch Østergren (ORCID: https://orcid.org/0000-0003-4762-039X)
- Klara Kvorning Ternov (ORCID: https://orcid.org/0000-0002-5641-5630)
- Ola Bratt (ORCID: https://orcid.org/0000-0002-9198-9445)
- Ganesh S. Palapattu (ORCID: https://orcid.org/0000-0002-9520-0480)
- Henriette Lindberg (ORCID: https://orcid.org/0000-0002-5191-3016)
- Mikkel Mejlgaard Fode (ORCID: https://orcid.org/0000-0002-8963-4581)
- Jens Sønksen (ORCID: https://orcid.org/0000-0002-5749-7279)
- Rasmus Bisbjerg (ORCID: https://orcid.org/0000-0001-6468-389X)
Institutions
- University of Copenhagen (DK)
- Sahlgrenska University Hospital (SE)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Michigan Medicine (US)
- Medical University of Vienna (AT)
- University of Gothenburg (SE)
Publication Details
- Journal
- Clinical Genitourinary Cancer
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1016/j.clgc.2024.102200
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gentofte Hospital